Synergy Between Trastuzumab and Pertuzumab for Human Epidermal Growth Factor 2 (Her2) From Colocalization: An in Silicobased Mechanism

Breast Cancer Research - United Kingdom
doi 10.1186/bcr2888
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

Cancer
Cancer ResearchOncology
2019English

Pertuzumab and Trastuzumab: The Rationale Way to Synergy

Anais da Academia Brasileira de Ciencias
Multidisciplinary
2016English

Pertuzumab in Human Epidermal Growth-Factor Receptor 2-Positive Breast Cancer: Clinical and Economic Considerations

International Journal of Women's Health
GynecologyOncologyMidwiferyMaternityObstetrics
2014English

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Human Epidermal Growth Factor 2 (HER2) Non-Small Cell Lung Cancer (NSCLC) With YVMA Mutation Responsive to Ado-Trastuzumab Emtansine

Journal of Case Reports and Images in Oncology
2020English

FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2017English

Correction: Cryo-Em Structure of HER2-trastuzumab-pertuzumab Complex

PLoS ONE
Multidisciplinary
2019English

Pertuzumab Increases Epidermal Growth Factor Receptor Down-Regulation by Counteracting Epidermal Growth Factor Receptor-ErbB2 Heterodimerization

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Ado-Trastuzumab Emtansine Targets Hepatocytes via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy